0000000000001347

AUTHOR

Francesco Verona

showing 7 related works from this author

Metabolic Escape Routes of Cancer Stem Cells and Therapeutic Opportunities

2020

Although improvement in early diagnosis and treatment ameliorated life expectancy of cancer patients, metastatic disease still lacks effective therapeutic approaches. Resistance to anticancer therapies stems from the refractoriness of a subpopulation of cancer cells—termed cancer stem cells (CSCs)—which is endowed with tumor initiation and metastasis formation potential. CSCs are heterogeneous and diverge by phenotypic, functional and metabolic perspectives. Intrinsic as well as extrinsic stimuli dictated by the tumor microenvironment (TME)have critical roles in determining cell metabolic reprogramming from glycolytic toward an oxidative phenotype and vice versa, allowing cancer cells to th…

cancer stem cells0301 basic medicinecancer stem cellCancer ResearchStromal cellSettore MED/50 - Scienze Tecniche Mediche ApplicateCellcancer metabolismReviewTumor initiationlcsh:RC254-282glycolysi03 medical and health sciences0302 clinical medicineCancer stem celllipid metabolismmicroRNAtumor microenvironmentmetabolic reprogrammingMedicinemetabolism-based anticancer drugsTumor microenvironmentbusiness.industryglycolysislcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOXPHOSMicrovesicles030104 developmental biologymedicine.anatomical_structureOncology030220 oncology & carcinogenesisCancer cellCancer researchSettore MED/46 - Scienze Tecniche Di Medicina Di LaboratoriobusinessCancers
researchProduct

Cancer Stem Cells and Neuroblastoma: Characteristics and Therapeutic Targeting Options

2019

The majority of embryonal tumors or childhood blastomas derive from pluripotent progenitors or fetal stem cells that acquire cancer stem cell (CSC) properties: multipotency, self-renewal ability, metastatic potential, chemoresistance, more pronounced levels of drug transporters, enhanced DNA-damage repair mechanisms, and a quiescent state. Neuroblastoma (NB) is considered a neuroendocrine tumor and is the most common extracranial neoplasm in children. NB pathogenesis has frequently been associated with epigenetic dysregulation and a failure to implement a differentiation program. The origin, characteristics, and isolation of the CSC subpopulation in NB are still incompletely understood, des…

cancer stem cells0301 basic medicinecancer stem cellEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismStem cell factorReviewBiologylcsh:Diseases of the endocrine glands. Clinical endocrinologySTAT303 medical and health sciencesneuroblastomaEndocrinology0302 clinical medicineCancer stem cellNeuroblastomamedicineanti-cancer therapiesProgenitor cellFetal Stem Cellsmesenchymal stem cellmesenchymal stem cellsTumor microenvironmentlcsh:RC648-665Mesenchymal stem cellanti-cancer therapiemedicine.disease030104 developmental biologyCancer researchReprogramming
researchProduct

Messing Up the Cancer Stem Cell Chemoresistance Mechanisms Supported by Tumor Microenvironment

2021

Despite the recent advances in cancer patient management and in the development of targeted therapies, systemic chemotherapy is currently used as a first-line treatment for many cancer types. After an initial partial response, patients become refractory to standard therapy fostering rapid tumor progression. Compelling evidence highlights that the resistance to chemotherapeutic regimens is a peculiarity of a subpopulation of cancer cells within tumor mass, known as cancer stem cells (CSCs). This cellular compartment is endowed with tumor-initiating and metastasis formation capabilities. CSC chemoresistance is sustained by a plethora of grow factors and cytokines released by neighboring tumor…

cancer stem cells0301 basic medicineCancer ResearchDNA repairmedicine.medical_treatmentReviewTargeted therapy03 medical and health sciences0302 clinical medicineImmune systemCancer stem celltumor microenvironmentMedicinecancer stem cells tumor microenvironment anticancer drugs chemoresistance targeted therapyRC254-282Tumor microenvironmentbusiness.industrychemoresistanceNeoplasms. Tumors. Oncology. Including cancer and carcinogensCancertargeted therapymedicine.diseaseanticancer drugs030104 developmental biologyOncologyTumor progression030220 oncology & carcinogenesisCancer cellCancer researchSettore MED/46 - Scienze Tecniche Di Medicina Di Laboratoriobusiness
researchProduct

Cancer Stem Cells in Thyroid Tumors: From the Origin to Metastasis

2020

Thyroid tumors are extremely heterogeneous varying from almost benign tumors with good prognosis as papillary or follicular tumors, to the undifferentiated ones with severe prognosis. Recently, several models of thyroid carcinogenesis have been described, mostly hypothesizing a major role of the thyroid cancer stem cell (TCSC) population in both cancer initiation and metastasis formation. However, the cellular origin of TCSC is still incompletely understood. Here, we review the principal epigenetic mechanisms relevant to TCSC origin and maintenance in both well-differentiated and anaplastic thyroid tumors. Specifically, we describe the alterations in DNA methylation, histone modifiers, and …

0301 basic medicinecancer stem cellsEndocrinology Diabetes and Metabolismthyroid tumors030209 endocrinology & metabolismTumor initiationReviewBiologymedicine.disease_causelcsh:Diseases of the endocrine glands. Clinical endocrinologyMetastasisHistones03 medical and health sciences0302 clinical medicineEndocrinologyCancer stem cellmedicineTumor MicroenvironmentHumansThyroid NeoplasmsNeoplasm MetastasisThyroid cancerTumor microenvironmentlcsh:RC648-665ThyroidCancerDNA Methylationmedicine.diseasemicroenvironmentMicroRNAsimmune system030104 developmental biologymedicine.anatomical_structureepigenetic alterationsCancer researchNeoplastic Stem CellsCarcinogenesis
researchProduct

Dual Inhibition of Myc Transcription and PI3K Activity Effectively Targets Colorectal Cancer Stem Cells

2022

Despite advances in the curative approach, the survival rate of advanced colorectal cancer (CRC) patients is still poor, which is likely due to the emergence of cancer cell clones resistant to the available therapeutic options. We have already shown that CD44v6-positive CRC stem cells (CR-CSCs) are refractory toward standard anti-tumor therapeutic agents due to the activation of the PI3K pathway together with high HER2 expression levels. Tumor microenvironmental cytokines confer resistance to CR-CSCs against HER2/PI3K targeting by enhancing activation of the MAPK pathway. Here, we show that the CSC compartment, spared by BRAF inhibitor-based targeted therapy, is associated with increased ex…

cancer stem cellsCancer ResearchOncologySettore MED/04 - PATOLOGIA GENERALECancer stem cellCombination therapies.anti-tumor drug resistanceanti-tumor drug resistance; colorectal cancer; combination therapies; cancer stem cellsNeoplasms. Tumors. Oncology. Including cancer and carcinogenscolorectal cancerSettore MED/46 - Scienze Tecniche Di Medicina Di Laboratoriocombination therapiesRC254-282Cancers
researchProduct

Recapitulating thyroid cancer histotypes through engineering embryonic stem cells

2023

AbstractThyroid carcinoma (TC) is the most common malignancy of endocrine organs. The cell subpopulation in the lineage hierarchy that serves as cell of origin for the different TC histotypes is unknown. Human embryonic stem cells (hESCs) with appropriate in vitro stimulation undergo sequential differentiation into thyroid progenitor cells (TPCs-day 22), which maturate into thyrocytes (day 30). Here, we create follicular cell-derived TCs of all the different histotypes based on specific genomic alterations delivered by CRISPR-Cas9 in hESC-derived TPCs. Specifically, TPCs harboring BRAFV600E or NRASQ61R mutations generate papillary or follicular TC, respectively, whereas addition of TP53R248…

MultidisciplinaryGeneral Physics and AstronomyGeneral ChemistryGeneral Biochemistry Genetics and Molecular BiologyThyroid cancer thyroid progenitor cells genetic mutation model CD44 TIMP1 KISS1 KISS1R.
researchProduct

Effective targeting of breast cancer stem cells by combined inhibition of Sam68 and Rad51

2022

AbstractBreast cancer (BC) is the second cause of cancer-related deceases in the worldwide female population. Despite the successful treatment advances, 25% of BC develops resistance to current therapeutic regimens, thereby remaining a major hurdle for patient management. Current therapies, targeting the molecular events underpinning the adaptive resistance, still require effort to improve BC treatment. Using BC sphere cells (BCSphCs) as a model, here we showed that BC stem-like cells express high levels of Myc, which requires the presence of the multifunctional DNA/RNA binding protein Sam68 for the DNA-damage repair. Analysis of a cohort of BC patients displayed that Sam68 is an independen…

cancer stem cellCancer Researchtherapy resistanceDNA RepairSettore MED/50 - Scienze Tecniche Mediche ApplicateCell Cycle ProteinsBreast NeoplasmsTriple Negative Breast NeoplasmsMycCell LineBreast cancerSettore MED/04 - PATOLOGIA GENERALECell Line TumorGeneticsHumansMolecular BiologyAdaptor Proteins Signal TransducingTumorSignal TransducingRNA-Binding ProteinsAdaptor ProteinsDNA-Binding ProteinsSam68Neoplastic Stem CellsFemaleRad51 RecombinaseSettore MED/46 - Scienze Tecniche Di Medicina Di Laboratorio
researchProduct